SCHEMBL20189142

SCHEMBL20189142

NCc1ccc(CN2CC(=O)NC2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.47
DDB1 Q16531 2/20 0.47
CRBN Q96SW2 2/20 0.47
GAA P10253 1/20 0.45
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.38
CA2 P00918 1/20 0.36
NCF1 P14598 1/20 0.36
CHKA P35790 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ENPP2 Q13822 1/20 0.36
HRH3 Q9Y5N1 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8009140 0.86 EPHX2 (0.47) EPHX2DDB1CRBNGAAHDAC2
SCHEMBL9164640 0.84 EPHX2 (0.49) EPHX2DDB1CRBNGAAHDAC2
SCHEMBL28757730 0.82 EPHX2 (0.47) EPHX2DDB1CRBNGAAHDAC2
SCHEMBL840894 0.82 EPHX2 (0.47) EPHX2DDB1CRBNGAAHDAC2
SCHEMBL9850086 0.81 DDB1 (0.69) EPHX2DDB1CRBNGAAHDAC2
SCHEMBL1011633 0.81 DDB1 (0.69) EPHX2DDB1CRBNGAAHDAC2
SCHEMBL20189877 0.80 GAA (0.44) EPHX2DDB1CRBNGAAHDAC2
SCHEMBL9850110 0.80 DDB1 (0.67) EPHX2DDB1CRBNGAAHDAC2
SCHEMBL2001787 0.79 ENPP2 (0.57) EPHX2DDB1CRBNGAAHDAC2
SCHEMBL22144492 0.79 EPHX2 (0.47) EPHX2DDB1CRBNGAAHDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168059-B2 Amino sulfonyl compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-09 US disclosed
US-11168059-B2 Amino sulfonyl compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-09 US disclosed
US-20190330158-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 US disclosed
US-20190330158-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 US disclosed
WO-2018098209-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168059-B2 Amino sulfonyl compounds DPYD, DNPEP, DUT EPHX2 2947/4885DDB1 33/4885CRBN 1595/4885
US-20190330158-A1 AMINO SULFONYL COMPOUNDS DPYD, DNPEP, DUT EPHX2 2947/4885DDB1 33/4885CRBN 1595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.